

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

BlackRock Health Sciences Trust
Form N-Q
November 21, 2018

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM N-Q

**QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number: 811-21702

Name of Fund: BlackRock Health Sciences Trust (BME)

Fund Address: 100 Bellevue Parkway, Wilmington, DE 19809

Name and address of agent for service: John M. Perlowski, Chief Executive Officer, BlackRock Health Sciences Trust, 55 East 52nd Street, New York, NY 10055

Registrant's telephone number, including area code: (800) 882-0052, Option 4

Date of fiscal year end: 12/31/2018

Date of reporting period: 09/30/2018

Item 1 Schedule of Investments

Schedule of Investments (unaudited)

BlackRock Health Sciences Trust (BME)

September 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Common Stocks 99.1%		
Biotechnology 18.4%		
ACADIA Pharmaceuticals, Inc. ^{(a)(b)}	37,400	\$ 776,424
Acceleron Pharma, Inc. ^{(a)(b)}	38,000	2,174,740
Acerta Pharma BV, Series B, (Acquired 02/01/16, cost \$986,402) ^{(c)(d)}	17,146,440	1,844,957
Agios Pharmaceuticals, Inc. ^{(a)(b)}	15,700	1,210,784
Alexion Pharmaceuticals, Inc. ^{(a)(b)}	26,900	3,739,369
Allakos, Inc. ^(a)	6,012	270,480
Alnylam Pharmaceuticals, Inc. ^{(a)(b)}	8,200	717,664
Amgen, Inc. ^(b)	28,460	5,899,473
Amicus Therapeutics, Inc. ^(a)	22,430	271,179
AnaptysBio, Inc. ^(a)	2,100	209,517
Apellis Pharmaceuticals, Inc. ^(a)	14,547	258,646
Arena Pharmaceuticals, Inc. ^{(a)(b)}	25,144	1,157,127
Biogen, Inc. ^{(a)(b)}	24,748	8,743,716
Biohaven Pharmaceutical Holding Co. Ltd. ^{(a)(b)}	7,050	264,728
BioMarin Pharmaceutical, Inc. ^{(a)(b)}	32,700	3,170,919
Bluebird Bio, Inc. ^{(a)(b)}	2,200	321,200
Blueprint Medicines Corp. ^{(a)(b)}	3,500	273,210
Cellectis SA, ADR ^(a)	15,095	425,981
Checkpoint Therapeutics, Inc. ^{(a)(e)}	43,100	154,298
Corbus Pharmaceuticals Holdings, Inc. ^(a)	38,600	291,430
Cytokinetics, Inc. ^(a)	11,300	111,305
Eidos Therapeutics, Inc. ^(a)	7,886	78,702
Galapagos NV, ADR ^{(a)(b)}	5,700	640,851
Gilead Sciences, Inc. ^(b)	37,500	2,895,375
Halozyme Therapeutics, Inc. ^{(a)(b)}	29,700	539,649
Incyte Corp. ^{(a)(b)}	34,400	2,376,352
InflaRx NV ^(a)	29,508	1,012,715
InflaRx NV, (Acquired 11/08/17, cost \$253,349) ^(d)	19,488	668,828
Insmed, Inc. ^{(a)(b)}	49,686	1,004,651
Intercept Pharmaceuticals, Inc. ^{(a)(b)}	2,600	328,536
Madrigal Pharmaceuticals, Inc. ^(a)	2,100	449,673
Neurocrine Biosciences, Inc. ^{(a)(b)}	9,400	1,155,730
Ovid therapeutics, Inc. ^(a)	42,053	238,441
Principia Biopharma, Inc. ^(a)	4,047	118,253
Ra Pharmaceuticals, Inc. ^(a)	6,500	117,585
Regeneron Pharmaceuticals, Inc. ^{(a)(b)}	6,758	2,730,502
Rubius Therapeutics, Inc. ^{(a)(d)}	2,991	71,784
Sage Therapeutics, Inc. ^{(a)(b)}	13,652	1,928,345
Sarepta Therapeutics, Inc. ^{(a)(b)}	38,950	6,290,814
Seattle Genetics, Inc. ^{(a)(b)}	50,967	3,930,575

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

Spark Therapeutics, Inc. ^{(a)(b)}	9,010	491,495
Spectrum Pharmaceuticals, Inc. ^{(a)(b)}	55,800	937,440
Sutro Biopharma, Inc. ^(a)	5,660	84,900
Syndax Pharmaceuticals, Inc. ^{(a)(b)}	15,784	127,535
TESARO, Inc. ^(a)	17,831	695,587
Ultragenyx Pharmaceutical, Inc. ^{(a)(b)}	17,500	1,335,950
<i>Security</i>	<i>Shares</i>	<i>Value</i>
Biotechnology (continued)		
Vertex Pharmaceuticals, Inc. ^{(a)(b)}	41,005	\$ 7,903,304
		70,440,719
Diversified Consumer Services 0.7%		
Service Corp. International	59,800	2,643,160
Health Care Equipment & Supplies 26.9%		
Abbott Laboratories ^(b)	252,800	18,545,408
Baxter International, Inc. ^(b)	74,300	5,727,787
Becton Dickinson & Co. ^(b)	27,933	7,290,513
Boston Scientific Corp. ^{(a)(b)}	420,284	16,180,934
Edwards Lifesciences Corp. ^{(a)(b)}	23,200	4,039,120
Establishment Labs Holdings, Inc. ^(a)	6,058	145,998
Globus Medical, Inc., Class A ^{(a)(b)}	24,700	1,401,972
Intuitive Surgical, Inc. ^{(a)(b)}	12,200	7,002,800
iRhythm Technologies, Inc. ^{(a)(b)}	15,183	1,437,223
Masimo Corp. ^(a)	39,000	4,857,060
Medtronic PLC ^(b)	170,900	16,811,433
Nevro Corp. ^{(a)(b)}	14,244	811,908
ResMed, Inc. ^(b)	32,200	3,713,948
Stryker Corp. ^(b)	53,600	9,523,648
Teleflex, Inc. ^(b)	8,500	2,261,765
Varian Medical Systems, Inc. ^{(a)(b)}	14,900	1,667,757
Zimmer Biomet Holdings, Inc. ^(b)	11,900	1,564,493
		102,983,767
Health Care Providers & Services 21.9%		
Amedisys, Inc. ^{(a)(b)}	24,960	3,119,002
AmerisourceBergen Corp. ^(b)	16,400	1,512,408
Anthem, Inc. ^(b)	35,800	9,810,990
Centene Corp. ^{(a)(b)}	42,800	6,196,584
Cigna Corp. ^(b)	37,100	7,726,075
DaVita, Inc. ^{(a)(b)}	17,594	1,260,258
HCA Healthcare, Inc. ^(b)	21,594	3,004,157
HealthEquity, Inc. ^{(a)(b)}	12,400	1,170,684
Humana, Inc. ^(b)	27,800	9,410,856
Molina Healthcare, Inc. ^{(a)(b)}	7,400	1,100,380
Quest Diagnostics, Inc. ^(b)	61,500	6,636,465
UnitedHealth Group, Inc.	115,802	30,807,964
WellCare Health Plans, Inc. ^{(a)(b)}	6,200	1,987,038
		83,742,861
Health Care Technology 0.8%		

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

Teladoc, Inc. ^{(a)(b)}	37,200	3,212,220
Life Sciences Tools & Services 4.5%		
Agilent Technologies, Inc. ^(b)	25,100	1,770,554
Charles River Laboratories International, Inc. ^{(a)(b)}	9,300	1,251,222
Illumina, Inc. ^{(a)(b)}	5,400	1,982,124
IQVIA Holdings, Inc. ^{(a)(b)}	10,300	1,336,322
PerkinElmer, Inc. ^(b)	9,800	953,246
QIAGEN NV ^{(a)(b)}	48,800	1,848,544
Thermo Fisher Scientific, Inc. ^(b)	27,600	6,736,608

Schedule of Investments (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

September 30, 2018

(Percentages shown are based on Net Assets)

<i>Security</i>	<i>Shares</i>	<i>Value</i>
Life Sciences Tools & Services (continued)		
Wuxi Biologics Cayman, Inc. ^{(a)(f)}	120,500	\$ 1,219,412
		17,098,032
Pharmaceuticals 25.9%		
Allergan PLC ^(b)	35,285	6,721,087
Arvinas Holding Co. LLC ^(a)	4,630	78,108
Assembly Biosciences, Inc. ^{(a)(b)}	5,033	186,926
AstraZeneca PLC ^(b)	70,276	5,477,596
AstraZeneca PLC ADR	63,700	2,520,609
Bristol-Myers Squibb Co. ^(b)	153,962	9,557,961
Chugai Pharmaceutical Co. Ltd.	16,100	1,034,961
Elanco Animal Health, Inc. ^(a)	10,891	379,987
Eli Lilly & Co. ^{(b)(c)}	66,400	7,125,384
Hua Medicine (Acquired 03/13/18, Cost \$505,000), 0.00% ^(d)	405,105	408,226
Hua Medicine ^{(a)(f)}	314,500	332,243
Jazz Pharmaceuticals PLC ^{(a)(b)}	10,500	1,765,365
Johnson & Johnson ^(b)	66,770	9,225,611
Medicines Co. ^{(a)(b)}	18,800	562,308
Merck & Co., Inc. ^(b)	167,679	11,895,148
Merck KGaA	28,300	2,923,975
Nektar Therapeutics ^{(a)(b)}	7,400	451,104
Novartis AG, ADR ^(b)	22,300	1,921,368
Novo Nordisk A/S ADR ^(b)	75,100	3,540,214
Pfizer, Inc. ^(b)	491,398	21,655,910
Reata Pharmaceuticals, Inc., Class A ^{(a)(b)}	9,419	770,097
Sanofi	20,600	1,840,552
Sanofi ADR	50,700	2,264,769
Teva Pharmaceutical Industries Ltd. ADR ^(b)	59,000	1,270,860
Theravance Biopharma, Inc. ^{(a)(b)}	4,700	153,549
Tricida, Inc. ^(a)	9,249	282,557
Urovant Sciences, Ltd. ^(a)	6,639	79,668
Zoetis, Inc. ^(b)	54,500	4,990,020
		99,416,163
Total Common Stocks 99.1% (Cost \$230,168,128)		379,536,922
Security	Shares	Value
Corporate Bonds 0.1%		
Allogene Therapeutics, Inc. (Acquired 08/31/18, Cost \$505,000), 0.00% ^{(c)(d)}	505,000	\$ 505,000

Total Corporate Bonds 0.1%		
(Cost \$505,000)		505,000
Other Interests^(g) 0.0%		
United States 0.0%		
Afferent Pharmaceuticals, Inc., Series C ^(c)	190	117,899
Total Other Interests 0.0%		
(Cost \$)		117,899
Preferred Stock		
Biotechnology 0.3%		
Rubius Therapeutics, Inc., (Acquired 02/23/18, Cost \$505,410), 0.00% ^{(c)(d)}	39,516	919,932
Total Preferred Stocks 0.3%		
(Cost \$505,409)		919,932
Total Long-Term Investments 99.5%		
(Cost \$231,178,537)		381,079,753
Short-Term Securities 1.4%		
BlackRock Liquidity Funds, T-Fund, Institutional Class, 1.97% ^{(h)(j)}	5,349,621	5,349,621
SL Liquidity Series, LLC, Money Market Series, 2.26% ^{(h)(i)(j)}	800	800
Total Short-Term Securities 1.4%		
(Cost \$5,350,421)		5,350,421
Total Investments Before Options Written 100.9%		
(Cost \$236,528,958)		386,430,174
Options Written (1.4)%		
(Premiums Received \$2,857,084)		(5,251,576)
Total Investments, Net of Options Written 99.5%		
(Cost \$233,671,874)		381,178,598
Other Assets Less Liabilities 0.5%		1,982,531
Net Assets 100.0%		\$ 383,161,129

(a) Non-income producing security.

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

- (b) All or a portion of the security has been pledged and/or segregated as collateral in connection with outstanding exchange-traded options written.
- (c) Security is valued using significant unobservable inputs and is classified as Level 3 in the fair value hierarchy.
- (d) Restricted security as to resale, excluding 144A securities. As of period end, the Trust held restricted securities with a current value of \$4,346,943 and an original cost of \$2,593,097, which was 0.7% of its net assets.

Schedule of Investments (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

September 30, 2018

- (e) Security, or a portion of the security, is on loan.
- (f) Security exempt from registration pursuant to Rule 144A under the Securities Act of 1933, as amended. These securities may be resold in transactions exempt from registration to qualified institutional investors.
- (g) Other interests represent beneficial interests in liquidation trusts and other reorganization or private entities.
- (h) Annualized 7-day yield as of period end.
- (i) Security was purchased with the cash collateral from loaned securities.
- (j) During the period ended September 30, 2018, investments in issuers considered to be affiliates of the Trust for purposes of Section 2(a)(3) of the Investment Company Act of 1940, as amended, and/or related parties of the Trust were as follows:

<i>Affiliate</i>	<i>Shares Held at 12/31/17</i>	<i>Net Activity</i>	<i>Shares Held at 09/30/18</i>	<i>Value at 09/30/18</i>	<i>Income</i>	<i>Realized Gain (Loss)</i>	<i>Change in Unrealized Appreciation (Depreciation)</i>
BlackRock Liquidity Funds, T-Fund, Institutional Class	14,301,421	(8,951,800)	5,349,621	\$ 5,349,621	\$ 107,994	\$	\$
SL Liquidity Series, LLC, Money Market Series	120,903	(120,103)	800	800	1,261 ^(b)	10	7
				\$ 5,350,421	\$ 109,255	\$ 10	\$ 7

(a) Includes net capital gain distributions, if applicable.

(b) Represents securities lending income earned from the reinvestment of cash collateral from loaned securities, net of fees and collateral investment expenses, and other payments to and from borrowers of securities.

For Trust compliance purposes, the Trust's sector classifications refer to one or more of the sector sub-classifications used by one or more widely recognized market indexes or rating group indexes, and/or as defined by the investment adviser. These definitions may not apply for purposes of this report, which may combine such sector sub-classifications for reporting ease.

Currency Abbreviations

EUR	Euro
GBP	British Pound
HKD	Hong Kong Dollar
JPY	Japanese Yen
USD	United States Dollar

Portfolio Abbreviations

ADR American Depositary Receipts

Derivative Financial Instruments Outstanding as of Period End**Exchange-Traded Options Written**

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional Amount (000)</i>	<i>Value</i>
<i>Call</i>					
Arena Pharmaceuticals, Inc.	16	10/04/18	USD 39.15	USD 74	\$ (11,019)
Abbott Laboratories	492	10/05/18	USD 67.50	USD 3,609	(295,200)
Alexion Pharmaceuticals, Inc.	65	10/05/18	USD 125.00	USD 904	(91,000)
Allergan PLC	78	10/05/18	USD 192.50	USD 1,486	(8,229)
Baxter International, Inc.	72	10/05/18	USD 74.50	USD 555	(19,296)
Biogen, Inc.	8	10/05/18	USD 350.00	USD 283	(5,920)
Bristol-Myers Squibb Co.	223	10/05/18	USD 62.00	USD 1,384	(11,373)
Humana, Inc.	22	10/05/18	USD 335.00	USD 745	(10,340)
Illumina, Inc.	21	10/05/18	USD 365.00	USD 771	(12,075)
Johnson & Johnson	33	10/05/18	USD 136.00	USD 456	(8,250)
Medtronic PLC	30	10/05/18	USD 95.01	USD 295	(10,473)
Merck & Co., Inc.	28	10/05/18	USD 69.00	USD 199	(5,838)
Pfizer, Inc.	365	10/05/18	USD 40.05	USD 1,609	(147,367)
AstraZeneca PLC	128	10/12/18	USD 37.50	USD 506	(38,720)

Schedule of Investments (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

September 30, 2018

Exchange-Traded Options Written (continued)

<i>Description</i>	<i>Number of Contracts</i>	<i>Expiration Date</i>	<i>Exercise Price</i>	<i>Notional</i>		<i>Value</i>
				<i>Amount (000)</i>		
Baxter International, Inc.	71	10/12/18	USD 75.00	USD 547		\$ (16,756)
Cigna Corp.	148	10/12/18	USD 187.50	USD 3,082		(312,650)
HCA Healthcare, Inc.	55	10/12/18	USD 134.00	USD 765		(31,350)
Merck & Co., Inc.	54	10/12/18	USD 70.00	USD 383		(7,938)
Pfizer, Inc.	365	10/12/18	USD 40.15	USD 1,609		(144,351)
Sarepta Therapeutics, Inc.	155	10/12/18	USD 150.00	USD 2,503		(254,975)
ACADIA Pharmaceuticals, Inc.	149	10/19/18	USD 15.00	USD 309		(91,635)
Abbott Laboratories	255	10/19/18	USD 67.50	USD 1,871		(151,725)
Accelaron Pharma, Inc.	152	10/19/18	USD 60.00	USD 870		(23,940)
Agilent Technologies, Inc.	100	10/19/18	USD 70.00	USD 705		(13,800)
Agios Pharmaceuticals, Inc.	62	10/19/18	USD 80.00	USD 478		(12,555)
Alnylam Pharmaceuticals, Inc.	32	10/19/18	USD 105.00	USD 280		(800)
Amedisys, Inc.	106	10/19/18	USD 125.00	USD 1,325		(36,570)
AmerisourceBergen Corp.	21	10/19/18	USD 87.50	USD 194		(10,815)
Amgen, Inc.	72	10/19/18	USD 200.00	USD 1,492		(61,920)
Anthem, Inc.	145	10/19/18	USD 280.00	USD 3,974		(28,565)
Assembly Biosciences, Inc.	20	10/19/18	USD 45.00	USD 74		(4,500)
Baxter International, Inc.	141	10/19/18	USD 77.50	USD 1,087		(13,042)
Becton Dickinson & Co.	62	10/19/18	USD 260.00	USD 1,618		(26,040)
BioMarin Pharmaceutical, Inc.	65	10/19/18	USD 105.00	USD 630		(3,412)
Biogen, Inc.	27	10/19/18	USD 355.00	USD 954		(20,925)
Biohaven Pharmaceutical Holding Co., Ltd.	28	10/19/18	USD 40.00	USD 105		(3,010)
Bluebird Bio, Inc.	10	10/19/18	USD 160.00	USD 146		(2,250)
Blueprint Medicines Corp.	14	10/19/18	USD 75.00	USD 109		(7,910)
Boston Scientific Corp.	670	10/19/18	USD 35.00	USD 2,580		(217,750)
Bristol-Myers Squibb Co.	170	10/19/18	USD 62.50	USD 1,055		(12,580)
Centene Corp.	150	10/19/18	USD 150.00	USD 2,172		(12,750)
Charles River Laboratories International, Inc.	37	10/19/18	USD 130.00	USD 498		(20,720)
DaVita, Inc.	70	10/19/18	USD 72.50	USD 501		(13,300)
Edwards Lifesciences Corp.	33	10/19/18	USD 150.00	USD 575		(81,180)
Eli Lilly & Co.	130	10/19/18	USD 106.75	USD 1,395		(32,364)
Galapagos NV	22	10/19/18	USD 120.00	USD 247		(4,400)
HCA Healthcare, Inc.	31	10/19/18	USD 135.00	USD 431		(17,360)
Halozyne Therapeutics, Inc.	135	10/19/18	USD 18.00	USD 245		(9,787)
HealthEquity, Inc.	49	10/19/18	USD 95.00	USD 463		(11,392)
Incyte Corp.	137	10/19/18	USD 70.00	USD 946		(26,373)

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

Insmed, Inc.	198	10/19/18	USD	22.00	USD	400	(44,550)
Intercept Pharmaceuticals, Inc.	10	10/19/18	USD	120.00	USD	126	(9,650)
Jazz Pharmaceuticals PLC	42	10/19/18	USD	165.00	USD	706	(21,840)
Johnson & Johnson	100	10/19/18	USD	140.00	USD	1,382	(14,500)
Medtronic PLC	146	10/19/18	USD	100.00	USD	1,436	(9,490)
Merck & Co., Inc.	149	10/19/18	USD	67.50	USD	1,057	(55,503)
Molina Healthcare, Inc.	30	10/19/18	USD	155.00	USD	446	(4,425)
Nektar Therapeutics	29	10/19/18	USD	70.00	USD	177	(2,610)
Neurocrine Biosciences, Inc.	37	10/19/18	USD	125.00	USD	455	(11,840)
Nevro Corp.	77	10/19/18	USD	65.00	USD	439	(14,630)
Novartis AG, ADR	19	10/19/18	USD	85.00	USD	164	(4,085)
Novo Nordisk A/S ADR	31	10/19/18	USD	49.00	USD	146	(620)
Pfizer, Inc.	365	10/19/18	USD	40.25	USD	1,609	(141,363)
Reata Pharmaceuticals, Inc., Class A	37	10/19/18	USD	95.00	USD	303	(6,475)
Regeneron Pharmaceuticals, Inc.	16	10/19/18	USD	410.00	USD	646	(13,440)
ResMed, Inc.	128	10/19/18	USD	115.00	USD	1,476	(25,920)
Sage Therapeutics, Inc.	16	10/19/18	USD	165.00	USD	226	(1,680)

Schedule of Investments (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

September 30, 2018

Exchange-Traded Options Written (continued)

Description	Number of Contracts	Expiration Date	Exercise Price	Notional	
				Amount (000)	Value
Sage Therapeutics, Inc.	39	10/19/18	USD 155.00	USD 551	\$ (5,070)
Seattle Genetics, Inc.	203	10/19/18	USD 80.00	USD 1,566	(29,943)
Spark Therapeutics, Inc.	36	10/19/18	USD 60.00	USD 196	(3,690)
Spectrum Pharmaceuticals, Inc.	223	10/19/18	USD 23.00	USD 375	(2,230)
Syndax Pharmaceuticals, Inc.	63	10/19/18	USD 10.00	USD 51	(2,520)
Teladoc, Inc.	148	10/19/18	USD 80.00	USD 1,278	(117,660)
Teleflex, Inc.	34	10/19/18	USD 270.00	USD 905	(10,540)
Teva Pharmaceutical Industries Ltd. ADR	84	10/19/18	USD 24.00	USD 181	(1,134)
Theravance Biopharma, Inc.	20	10/19/18	USD 30.00	USD 65	(6,700)
Thermo Fisher Scientific, Inc.	110	10/19/18	USD 250.00	USD 2,685	(13,475)
Varian Medical Systems, Inc.	59	10/19/18	USD 115.00	USD 660	(4,425)
Vertex Pharmaceuticals, Inc.	164	10/19/18	USD 185.00	USD 3,161	(163,180)
WellCare Health Plans, Inc.	23	10/19/18	USD 310.00	USD 737	(31,970)
Zimmer Biomet Holdings, Inc.	46	10/19/18	USD 125.00	USD 605	(32,200)
iRhythm Technologies, Inc.	60	10/19/18	USD 95.00	USD 568	(17,700)
Abbott Laboratories	221	10/26/18	USD 69.00	USD 1,621	(101,108)
Allergan PLC	63	10/26/18	USD 192.50	USD 1,200	(21,577)
Amgen, Inc.	7	10/26/18	USD 202.50	USD 145	(5,040)
AstraZeneca PLC	126	10/26/18	USD 38.50	USD 499	(46,620)
Baxter International, Inc.	47	10/26/18	USD 78.00	USD 362	(4,018)
Becton Dickinson & Co.	49	10/26/18	USD 262.50	USD 1,279	(16,905)
Biogen, Inc.	24	10/26/18	USD 350.00	USD 848	(37,560)
Bristol-Myers Squibb Co.	73	10/26/18	USD 62.00	USD 453	(10,402)
Humana, Inc.	21	10/26/18	USD 340.00	USD 711	(10,500)
Johnson & Johnson	102	10/26/18	USD 141.00	USD 1,409	(13,311)
Medtronic PLC	114	10/26/18	USD 97.00	USD 1,121	(29,013)
Merck & Co., Inc.	182	10/26/18	USD 70.50	USD 1,291	(31,941)
Pfizer, Inc.	196	10/26/18	USD 42.00	USD 864	(44,002)
Pfizer, Inc.	202	10/26/18	USD 41.69	USD 890	(53,204)
Teva Pharmaceutical Industries Ltd. ADR	152	10/26/18	USD 23.00	USD 327	(5,928)
Zoetis, Inc.	148	10/26/18	USD 90.50	USD 1,355	(31,820)
Novo Nordisk A/S ADR	103	10/31/18	USD 47.74	USD 486	(8,346)
Alexion Pharmaceuticals, Inc.	42	11/02/18	USD 137.00	USD 584	(31,290)
Amgen, Inc.	34	11/02/18	USD 207.50	USD 705	(17,850)
Biogen, Inc.	39	11/02/18	USD 345.00	USD 1,378	(72,930)
Bristol-Myers Squibb Co.	149	11/02/18	USD 63.00	USD 925	(16,911)

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

Eli Lilly & Co.	135	11/02/18	USD	107.00	USD	1,449	(34,223)
Gilead Sciences, Inc.	63	11/02/18	USD	75.00	USD	486	(23,940)
Humana, Inc.	68	11/02/18	USD	340.00	USD	2,302	(45,220)
Intuitive Surgical, Inc.	48	11/02/18	USD	562.50	USD	2,755	(129,120)
Johnson & Johnson	32	11/02/18	USD	141.00	USD	442	(4,992)
Medtronic PLC	319	11/02/18	USD	99.50	USD	3,138	(40,992)
Merck & Co., Inc.	137	11/02/18	USD	71.00	USD	972	(22,194)
Pfizer, Inc.	192	11/02/18	USD	43.00	USD	846	(30,144)
Novo Nordisk A/S ADR	103	11/06/18	USD	47.74	USD	486	(9,353)
AmerisourceBergen Corp.	44	11/16/18	USD	92.50	USD	406	(15,620)
Arena Pharmaceuticals, Inc.	84	11/16/18	USD	43.00	USD	387	(41,790)
BioMarin Pharmaceutical, Inc.	65	11/16/18	USD	105.00	USD	630	(11,862)
Centene Corp.	22	11/16/18	USD	143.50	USD	319	(13,459)
Edwards Lifesciences Corp.	39	11/16/18	USD	155.00	USD	679	(81,510)
Gilead Sciences, Inc.	87	11/16/18	USD	75.00	USD	672	(36,975)
IQVIA Holdings, Inc.	41	11/16/18	USD	140.00	USD	532	(4,715)
Medicine s Co.	75	11/16/18	USD	36.00	USD	224	(12,187)

Schedule of Investments (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

September 30, 2018

Exchange-Traded Options Written (continued)

Description	Number of Contracts	Expiration Date	Exercise		Notional		Value
			Price	Amount (000)	Amount (000)		
Medtronic PLC	74	11/16/18	USD	97.50	USD	728	\$ (20,979)
Merck & Co., Inc.	120	11/16/18	USD	72.50	USD	851	(14,400)
PerkinElmer, Inc.	39	11/16/18	USD	100.00	USD	379	(9,165)
Pfizer, Inc.	85	11/16/18	USD	44.00	USD	375	(8,670)
Pfizer, Inc.	195	11/16/18	USD	42.98	USD	859	(29,614)
QIAGEN NV	195	11/16/18	USD	40.00	USD	739	(56,550)
Quest Diagnostics, Inc.	247	11/16/18	USD	110.00	USD	2,665	(41,990)
Regeneron Pharmaceuticals, Inc.	11	11/16/18	USD	390.00	USD	444	(31,130)
Ultragenyx Pharmaceutical, Inc.	70	11/16/18	USD	90.00	USD	534	(21,000)
Zoetis, Inc.	70	11/16/18	USD	92.50	USD	641	(15,925)
Globus Medical, Inc., Class A	98	12/21/18	USD	55.00	USD	556	(46,550)
Stelco Holdings, Inc.	214	12/21/18	USD	175.00	USD	3,802	(163,710)
							\$ (4,869,803)

OTC Options Written

Description	Counterparty	Number of Contracts	Expiration Date	Exercise		Notional		Value
				Price	Amount (000)	Amount (000)		
Call								
Novo Nordisk A/S ADR	Barclays Bank PLC	6,400	10/01/18	USD	51.00	USD	302	\$
Chugai Pharmaceutical Co., Ltd.	JPMorgan Chase Bank N.A.	6,400	10/03/18	JPY	6,419.72	JPY	46,745	(50,018)
Novartis AG, ADR	UBS AG	7,000	10/03/18	USD	83.44	USD	603	(19,384)
Service Corp. International	Barclays Bank PLC	5,300	10/04/18	USD	42.03	USD	234	(11,697)
Masimo Corp. Service Corp. International	Goldman Sachs International	15,600	10/23/18	USD	123.10	USD	1,943	(58,551)
Merck KGaA	Barclays Bank PLC	18,600	10/23/18	USD	41.86	USD	822	(48,979)
Sanofi	Morgan Stanley & Co. International PLC	11,300	10/30/18	EUR	88.57	EUR	1,006	(28,109)
	Goldman Sachs International	8,200	10/31/18	EUR	77.19	EUR	631	(11,545)
	Barclays Bank PLC	28,100	11/01/18	GBP	57.00	GBP	1,680	(125,499)

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

AstraZeneca PLC										
Sanofi	ADR	Morgan Stanley & Co. International PLC	20,200	11/12/18	USD	44.10	USD	902	(27,991)	
										\$(381,773)

Schedule of Investments (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

September 30, 2018

Fair Value Hierarchy as of Period End

Various inputs are used in determining the fair value of investments and derivative financial instruments. These inputs to valuation techniques are categorized into a fair value hierarchy consisting of three broad levels for financial reporting purposes as follows:

Level 1 Unadjusted quoted prices in active markets/exchanges for identical assets or liabilities that Trust has the ability to access

Level 2 Other observable inputs (including, but not limited to, quoted prices for similar assets or liabilities in markets that are active, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the assets or liabilities (such as interest rates, yield curves, volatilities, prepayment speeds, loss severities, credit risks and default rates) or other market-corroborated inputs)

Level 3 Unobservable inputs based on the best information available in the circumstances, to the extent observable inputs are not available (including Trust's own assumptions used in determining the fair value of investments and derivative financial instruments)

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3. The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the fair value hierarchy classification is determined based on the lowest level input that is significant to the fair value measurement in its entirety. Investments classified within Level 3 have significant unobservable inputs used by the BlackRock Global Valuation Methodologies Committee (the Global Valuation Committee) in determining the price for Fair Valued Investments. Level 3 investments include equity or debt issued by privately held companies or funds. There may not be a secondary market, and/or there are a limited number of investors. Level 3 investments may also be adjusted to reflect illiquidity and/or non-transferability, with the amount of such discount estimated by the Global Valuation Committee in the absence of market information.

Changes in valuation techniques may result in transfers into or out of an assigned level within the hierarchy. In accordance with the Trust's policy, transfers between different levels of the fair value hierarchy are deemed to have occurred as of the beginning of the reporting period. The categorization of a value determined for investments and derivative financial instruments is based on the pricing transparency of the investments and derivative financial instruments and is not necessarily an indication of the risks associated with investing in those securities. For information about the Trust's policy regarding valuation of investments and derivative financial instruments, refer to the Trust's most recent financial statements as contained in its semi-annual report.

The following tables summarize the Trust's investments and derivative financial instruments categorized in the disclosure hierarchy:

Edgar Filing: BlackRock Health Sciences Trust - Form N-Q

	<i>Level 1</i>	<i>Level 2</i>	<i>Level 3</i>	<i>Total</i>
Assets:				
Investments:				
Common Stocks:				
Biotechnology	\$ 67,926,934	\$ 668,828	\$ 1,844,957	\$ 70,440,719
Diversified Consumer Services	2,643,160			2,643,160
Health Care Equipment & Supplies	102,983,767			102,983,767
Health Care Providers & Services	83,742,861			83,742,861
Health Care Technology	3,212,220			3,212,220
Life Sciences Tools & Services	15,878,620	1,219,412		17,098,032
Pharmaceuticals	87,730,853	11,277,084	408,226	99,416,163
Corporate Bonds			505,000	505,000
Other Interests			117,899	117,899
Preferred Stock			919,932	919,932
Short-Term Securities	5,349,621			5,349,621
	\$ 369,468,036	\$ 13,165,324	\$ 3,796,014	\$ 386,429,374
Investments Valued at NAV ^(a)				800
				\$ 386,430,174
Derivative Financial Instruments ^(b)				
Liabilities:				
Equity contracts	\$ (4,268,891)	\$ (982,685)	\$	\$ (5,251,576)

Schedule of Investments (unaudited) (continued)

BlackRock Health Sciences Trust (BME)

September 30, 2018

(a) As of September 30, 2018, certain of the Trust's Investments were fair valued using net asset value (NAV) per share and have been excluded from the fair value hierarchy.

(b) Derivative financial instruments are options written, which are shown at value.

Transfers between Level 1 and Level 2 were as follows:

	<i>Transfers into Level 1</i>	<i>Transfers out of Level 1 (a)</i>	<i>Transfers Into Level 2 (a)</i>	<i>Transfers out of Level 2</i>
Assets:				
Long-Term Investments:				
Common Stocks	\$	\$ 548,148	\$ 548,148	\$

(a) External pricing service used to reflect any significant market movements between the time the Trust valued such foreign securities and the earlier closing of foreign markets.

A reconciliation of Level 3 investments is presented when the Trust had a significant amount of Level 3 investments at the beginning and/or end of the period in relation to net assets. The following table is a reconciliation of Level 3 investments for which significant unobservable inputs were used in determining fair value:

	<i>Common Stocks</i>	<i>Preferred Stocks</i>	<i>Other Interests</i>	<i>Rights</i>	<i>Corporate Bonds</i>	<i>Total</i>
Assets:						
Opening Balance, as of December 31, 2017	\$ 1,916,972	\$	\$ 387,926	\$ 141,355	\$	\$ 2,446,253
Transfers into Level 3						
Transfers out of Level 3						
Accrued discounts/premiums						
Net realized gain (loss)				221,060		221,060
Net change in unrealized appreciation (depreciation) ^{(a)(b)}	(6,725)	414,523	(270,027)	(115,507)		22,264
Purchases	342,936	505,409			505,000	1,353,345
Sales				(246,908)		(246,908)

Closing Balance, as of September 30, 2018	\$ 2,253,183	\$ 919,932	\$ 117,899	\$	\$ 505,000	\$ 3,796,014
Net change in unrealized appreciation (depreciation) on investments still held at September 30, 2018 ^(b)	\$ (6,725)	\$ 414,523	\$ (270,027)	\$	\$	\$ (349,088)

^(a) Included in the related net change in unrealized appreciation (depreciation) in the Statements of Operations.

^(b) Any difference between net change in unrealized appreciation (depreciation) and net change in unrealized appreciation (depreciation) on derivative financial instruments still held at September 30, 2018 is generally due to derivative financial instruments no longer held or categorized as Level 3 at period end.

Item 2 Controls and Procedures

- 2(a) The registrant's principal executive and principal financial officers, or persons performing similar functions, have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940, as amended (the "1940 Act")) are effective as of a date within 90 days of the filing of this report based on the evaluation of these controls and procedures required by Rule 30a-3(b) under the 1940 Act and Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended.
- 2(b) There were no changes in the registrant's internal control over financial reporting (as defined in Rule 30a-3(d) under the 1940 Act) that occurred during the registrant's last fiscal quarter that have materially affected, or are reasonably likely to materially affect, the registrant's internal control over financial reporting.

Item 3 Exhibits

Certifications Attached hereto

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BlackRock Health Sciences Trust

By: /s/ John M. Perlowski
John M. Perlowski
Chief Executive Officer (principal executive officer) of
BlackRock Health Sciences Trust

Date: November 19, 2018

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By: /s/ John M. Perlowski
John M. Perlowski
Chief Executive Officer (principal executive officer) of
BlackRock Health Sciences Trust

Date: November 19, 2018

By: /s/ Neal J. Andrews
Neal J. Andrews
Chief Financial Officer (principal financial officer) of
BlackRock Health Sciences Trust

Date: November 19, 2018